Research Paper Volume 11, Issue 18 pp 7817—7829
PRL-3 exerts oncogenic functions in myeloid leukemia cells via aberrant dephosphorylation of stathmin and activation of STAT3 signaling
Figure 1. Expression of PRL-3 and stathmin in clinical samples and cell lines detected by western blot. (A–C) Expression of PRL-3 and stathmin in de novo myeloid leukemia patients. (D, E) Expression of PRL-3 and stathmin in myeloid leukemia cell lines. (*P<0.05, **P<0.01, vs. healthy normal control). Note: N, healthy normal control. P, de novo patient.